keyword
MENU ▼
Read by QxMD icon Read
search

liver cancer trial

keyword
https://www.readbyqxmd.com/read/29766659/prognosis-of-patients-with-hepatocellular-carcinoma-treated-with-sorafenib-a-comparison-of-five-models-in-a-large-canadian-database
#1
Haider H Samawi, Hao-Wen Sim, Kelvin K Chan, Mohammad A Alghamdi, Richard M Lee-Ying, Jennifer J Knox, Parneet Gill, Adriana Romagnino, Eugene Batuyong, Yoo-Joung Ko, Janine M Davies, Howard J Lim, Winson Y Cheung, Vincent C Tam
Several systems (tumor-node-metastasis [TNM], Barcelona Clinic Liver Cancer [BCLC], Okuda, Cancer of the Liver Italian Program [CLIP], and albumin-bilirubin grade [ALBI]) were developed to estimate the prognosis of patients with hepatocellular carcinoma (HCC) mostly prior to the prevalent use of sorafenib. We aimed to compare the prognostic and discriminatory power of these models in predicting survival for HCC patients treated with sorafenib and to identify independent prognostic factors for survival in this population...
May 15, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29764827/not-so-mass-effect-finding-of-a-remarkable-incidentaloma-in-a-teenager-with-neurofibromatosis
#2
Daniel John Keen, Hannah Norman-Bruce, Salah Mansy
A 13-year-old boy with neurofibromatosis type 1 presented to the emergency department twice in a fortnight with moderate intermittent abdominal pain, radiating to the back and associated with nausea and vomiting. He examined as a well child with a soft abdomen and minimal tenderness. A history of constipation was identified but he failed to respond to a trial of laxatives. Subsequent ultrasound abdomen demonstrated a large mass surrounding the porta hepatis. MRI further characterised a focal, non-aggressive lesion extending from his liver, encapsulating his pancreas, portal vessels and laterally displacing his spleen and left kidney...
May 14, 2018: BMJ Case Reports
https://www.readbyqxmd.com/read/29762149/pseudoadjuvant-chemotherapy-in-resectable-metastatic-colorectal-cancer
#3
Laura Polastro, Georges El Hachem, Alain Hendlisz
PURPOSE OF REVIEW: In this article, we focus on the potential benefits and risks of chemotherapy administration before (perioperative) or after (pseudoadjuvant) a curative resection of colorectal cancer (CRC) metastases. RECENT FINDINGS: In the published evidence, there is a lack of survival benefit from peri or postoperative chemotherapy in the context of resectable metastatic CRC. However, high-risk patients may have a certain benefit when receiving a postoperative cytotoxic treatment...
May 11, 2018: Current Opinion in Oncology
https://www.readbyqxmd.com/read/29752549/promising-new-agents-for-colorectal-cancer
#4
REVIEW
Satya Das, Kristen K Ciombor, Sigurdis Haraldsdottir, Richard M Goldberg
Choosing the optimal treatment approach for patients with metastatic colorectal cancer (mCRC) demands that oncologists assess both clinical and genomic variables and individualize care based upon the findings. Clinically, choices depend on assessing the side of the colon in which the primary tumor originates, the sites and burden of metastatic disease, the patient's performance status, and their individual comorbidities. Genomic assessment of the tumor to discern the mutational status of genes such as RAS/RAF, HER2, and TRK, as well as assessing whether tumors have defective mismatch repair (dMMR) or high microsatellite instability (MSI-H), all factor in to potential treatment options and can determine clinical trial eligibility...
May 11, 2018: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29752333/the-endocrinology-of-male-breast-cancer
#5
REVIEW
Ian S Fentiman
Male breast cancer (MBC) is a rare disease but, as a result of epidemiological collaborations, there is now greater clarity concerning endocrine risk factors. The significant rise in global age-standardised mean BMI in men is likely to lead to increases in incidence of maturity-onset diabetes and MBC. The metabolic changes accompanying obesity decrease androgens and sex hormone-binding globulin (SHBG), thereby increasing available oestrogens. The higher rates of MBC in North and Equatorial Africa are largely due to liver damage from endemic bilharziasis and hepatitis B causing elevated oestradiol (E2 ) levels from hepatic conversion of androgen...
June 2018: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29749446/anesthetic-effects-of-isoflurane-and-the-molecular-mechanism-underlying-isoflurane%C3%A2-inhibited-aggressiveness-of-hepatic-carcinoma
#6
Jing Hu, Jingli Hu, Hongmei Jiao, Qingguo Li
Anesthesia is produced by drugs or other methods, and refers to the attenuation of pain via reversible suppression of neuronal transmission in the central and peripheral nervous systems, during surgery. Clinical investigations have indicated that the anesthetic action of isoflurane is efficient to alleviate pain during tumor resection clinical trials. In addition, it has been reported that isoflurane can induce caspase‑3 activation and is associated with apoptosis of tumor cells. The present study investigated the anesthetic effects and molecular mechanisms underlying isoflurane‑induced apoptosis in patients with hepatic carcinoma...
May 2, 2018: Molecular Medicine Reports
https://www.readbyqxmd.com/read/29744867/p-glycoprotein-mdr1-abcb1-restricts-brain-accumulation-and-cytochrome-p450-3a-cyp3a-limits-oral-availability-of-the-novel-alk-ros1-inhibitor-lorlatinib
#7
Wenlong Li, Rolf W Sparidans, Yaogeng Wang, Maria C Lebre, Els Wagenaar, Jos H Beijnen, Alfred H Schinkel
Lorlatinib (PF-06463922) is a promising oral anaplastic lymphoma kinase (ALK) and ROS1 inhibitor currently in Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC) containing an ALK rearrangement. With therapy-resistant brain metastases a major concern in NSCLC, lorlatinib was designed to have high membrane and blood-brain barrier permeability. We investigated the roles of the multidrug efflux transporters ABCB1 and ABCG2, and the multispecific drug-metabolizing enzyme CYP3A in plasma pharmacokinetics and tissue distribution of lorlatinib using genetically modified mouse strains...
May 9, 2018: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29743154/oncosurgical-management-of-liver-limited-stage-iv-colorectal-cancer-preliminary-data-and-protocol-for-a-randomized-controlled-trial
#8
Paul Sutton, Dale Vimalachandran, Graeme Poston, Stephen Fenwick, Hassan Malik
BACKGROUND: Colorectal cancer is the fourth commonest cancer and second commonest cause of cancer-related death in the United Kingdom. Almost 15% of patients have metastases on presentation. An increasing number of surgical strategies and better neoadjuvant treatment options are responsible for more patients undergoing resection of liver metastases, with prolonged survival in a select group of patients who present with synchronous disease. It is clear that the optimal strategy for the management of these patients remains unclear, and there is certainly a complete absence of Level 1 evidence in the literature...
May 9, 2018: JMIR Research Protocols
https://www.readbyqxmd.com/read/29743140/a-phase-i-single-arm-open-label-dose-escalation-study-of-intraperitoneal-cisplatin-and-doxorubicin-in-patients-with-recurrent-ovarian-cancer-and-peritoneal-carcinomatosis
#9
Clemens B Tempfer, Urs Giger-Pabst, Veronika Seebacher, Miriam Petersen, Askin Dogan, Günther A Rezniczek
OBJECTIVE: We performed a phase I, single-arm, non-randomized, open-label, dose-escalation trial to determine the dose-limiting toxicity of intraperitoneal cisplatin and doxorubicin applied as pressurized intraperitoneal aerosol chemotherapy (PIPAC) in women with recurrent ovarian cancer. METHODS: We used a standard 3 + 3 dose-escalation design with doxorubicin 1.5 mg/m2 , cisplatin 7.5 mg/m2 q 4 to 6 weeks for 3 cycles and subsequent dose escalation steps (20% increment per step) in patients with recurrent ovarian cancer and peritoneal carcinomatosis...
May 6, 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29736851/towards-volumetric-thresholds-in-recist-1-1-therapeutic-response-assessment-in-hepatic-metastases
#10
Katharina S Winter, Felix O Hofmann, Kolja M Thierfelder, Julian W Holch, Nina Hesse, Alena B Baumann, Dominik P Modest, Sebastian Stintzing, Volker Heinemann, Jens Ricke, Wieland H Sommer, Melvin D'Anastasi
OBJECTIVES: To empirically determine thresholds for volumetric assessment of response and progress of liver metastases in line with the unidimensional RECIST thresholds. METHODS: Patients with metastatic colorectal cancer initially enrolled in a multicentre clinical phase-III trial were included. In all CT scans, the longest axial diameters and volumes of hepatic lesions were determined semi-automatically. The sum of diameters and volumes of 1, ≤2 and ≤5 metastases were compared to all previous examinations...
May 7, 2018: European Radiology
https://www.readbyqxmd.com/read/29736699/performance-of-fdg-pet-ct-in-solitary-pulmonary-nodule-based-on-pre-test-likelihood-of-malignancy-results-from-the-italian-retrospective-multicenter-trial
#11
Laura Evangelista, Alberto Cuocolo, Leonardo Pace, Luigi Mansi, Silvana Del Vecchio, Paolo Miletto, Silvia Sanfilippo, Sara Pellegrino, Luca Guerra, Giovanna Pepe, Giuseppina Peluso, Marco Salvatore, Rosj Galicchio, Michele Zuffante, Salvatore Annunziata, Mohsen Farsad, Agostino Chiaravalloti, Marco Spadafora
PURPOSE: The aim of this study was to determine the performance of 18 F-FDG-PET/CT in patients with solitary pulmonary nodule (SPN), stratifying the risk according to the likelihood of pulmonary malignancy. METHODS: FDG-PET/CT of 502 patients, stratified for pre-test cancer risk, were retrospectively analyzed. FDG uptake in SPN was assessed by a 4-point scoring system and semiquantitative analysis using the ratio between SUVmax in SPN and SUVmean in mediastinal blood pool (BP) and between SUVmax in SPN and SUVmean in liver (L)...
May 7, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29733995/comparison-of-hepatoprotective-effect-from-ischemia-reperfusion-injury-of-remote-ischemic-preconditioning-of-the-liver-vs-local-ischemic-preconditioning-of-the-liver-during-human-liver-resections
#12
Mislav Rakić, Leonardo Patrlj, Fedor Amić, Gorana Aralica, Ivica Grgurević
AIM: To compare and evaluate the hepatoprotective effect of remote ischemic preconditioning (RIPC) with local ischemic preconditioning (LIPC) of the liver during human liver resections. METHODS: A prospective, single-centre, randomised control trial was conducted in the Clinical Hospital "***" from April 2017 to January 2018. A total of 60 patients, who underwent liver resection due to colorectal cancer liver metastasis, were randomised to one of three study arms: 1)a RIPC group, 2) an LIPC group and 3) a control group (CG) in which no ischemic preconditioning was done before liver resection...
May 4, 2018: International Journal of Surgery
https://www.readbyqxmd.com/read/29729190/baicalein-targets-gtpase-mediated-autophagy-to-eliminate-liver-tumor-initiating-stem-cell-like-cells-resistant-to-mtorc1-inhibition
#13
Raymond Wu, Ramachandran Murali, Yasuaki Kabe, Samuel W French, Yi-Ming Chiang, Siyu Liu, Linda Sher, Clay C Wang, Stan Louie, Hidekazu Tsukamoto
Drug resistance is a major problem in the treatment of liver cancer. mTORC1 inhibitors have been tested for the treatment of liver cancer based on hyperactive mTOR in this malignancy. However, their clinical trials showed poor outcome due likely to their ability to upregulate CD133 and promote chemoresistance. CD133+ tumor initiating stem cell-like cells (TICs) isolated from mouse and human liver tumors are chemoresistant, and identification of an approach to abrogate this resistance is desired. In search for a compound which rescinds TIC's resistance to mTORC1 inhibition and improves chemotherapy, we identified baicalein (BC) which selectively chemosensitizes TICs and the human HCC cell line Huh7 cells but not mouse and human primary hepatocytes...
May 5, 2018: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/29728772/implementing-a-mediterranean-style-diet-outside-the-mediterranean-region
#14
REVIEW
Karen J Murphy, Natalie Parletta
PURPOSE OF REVIEW: Populations surrounding the Mediterranean basin have traditionally reaped health benefits from a Mediterranean diet (MedDiet), which may benefit Westernized countries plagued by chronic disease. But is it feasible to implement beyond the Mediterranean? To answer this question, we present evidence from randomized controlled trials that achieved high dietary compliance rates with subsequent physical and mental health benefits. RECENT FINDINGS: In the 1960s, the Seven Countries Study identified dietary qualities of Mediterranean populations associated with healthy aging and longevity...
May 4, 2018: Current Atherosclerosis Reports
https://www.readbyqxmd.com/read/29721386/in-situ-delivery-of-allogeneic-natural-killer-cell-nk-combined-with-cetuximab-in-liver-metastases-of-gastrointestinal-carcinoma-a-phase-i-clinical-trial
#15
O Adotevi, Y Godet, J Galaine, Z Lakkis, I Idirene, J M Certoux, M Jary, R Loyon, C Laheurte, S Kim, A Dormoy, F Pouthier, C Barisien, F Fein, P Tiberghien, X Pivot, S Valmary-Degano, C Ferrand, P Morel, E Delabrousse, C Borg
Despite successful introduction of NK-based cellular therapy in the treatment of myeloid leukemia, the potential use of NK alloreactivity in solid malignancies is still elusive. We performed a phase I clinical trial to assess the safety and efficacy of in situ delivery of allogeneic NK cells combined with cetuximab in liver metastasis of gastrointestinal origin. The conditioning chemotherapy was administrated before the allogeneic NK cells injection via hepatic artery. Three escalating doses were tested (3...
2018: Oncoimmunology
https://www.readbyqxmd.com/read/29719210/cell-encapsulation-overcoming-barriers-in-cell-transplantation-in-diabetes-and-beyond
#16
Marco Farina, Jenolyn F Alexander, Usha Thekkedath, Mauro Ferrari, Alessandro Grattoni
Cell-based therapy is emerging as a promising strategy for treating a wide range of human diseases, such as diabetes, blood disorders, acute liver failure, spinal cord injury, and several types of cancer. Pancreatic islets, blood cells, hepatocytes, and stem cells are among the many cell types currently used for this strategy. The encapsulation of these "therapeutic" cells is under intense investigation to not only prevent immune rejection but also provide a controlled and supportive environment so they can function effectively...
April 29, 2018: Advanced Drug Delivery Reviews
https://www.readbyqxmd.com/read/29718092/updated-results-from-monaleesa-2-a-phase-iii-trial-of-first-line-ribociclib-plus-letrozole-versus-placebo-plus-letrozole-in-hormone-receptor-positive-her2-negative-advanced-breast-cancer
#17
G N Hortobagyi, S M Stemmer, H A Burris, Y S Yap, G S Sonke, S Paluch-Shimon, M Campone, K Petrakova, K L Blackwell, E P Winer, W Janni, S Verma, P Conte, C L Arteaga, D A Cameron, S Mondal, F Su, M Miller, M Elmeliegy, C Germa, J O'Shaughnessy
Background: The phase III MONALEESA-2 study demonstrated significantly prolonged progression-free survival (PFS) and a manageable toxicity profile for first-line ribociclib plus letrozole versus placebo plus letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. Here we report updated efficacy and safety data, together with exploratory biomarker analyses, from the MONALEESA-2 study. Patients and methods: A total of 668 postmenopausal women with HR+, HER2- recurrent/metastatic breast cancer were randomized (1:1; stratified by presence/absence of liver and/or lung metastases) to ribociclib (600 mg/day; 3-weeks-on/1-week-off; 28-day treatment cycles) plus letrozole (2...
April 27, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29716923/interferon-gamma-messenger-rna-signature-in-tumor-biopsies-predicts-outcomes-in-patients-with-non-small-cell-lung-carcinoma-or-urothelial-cancer-treated-with-durvalumab
#18
Brandon W Higgs, Christopher Morehouse, Katie L Streicher, Philip Brohawn, Fernanda Pilataxi, Ashok Gupta, Koustubh Ranade
PURPOSE: To identify a predictive biomarker for durvalumab, an anti-programmed death ligand 1 (PD-L1) monoclonal antibody. EXPERIMENTAL DESIGN: RNA sequencing of 97 advanced-stage non-small-cell lung carcinoma (NSCLC) biopsies from a nonrandomized phase 1b/2 clinical trial (1108/NCT01693562) were profiled to identify a predictive signature; 62 locally advanced or metastatic urothelial cancer (UC) tumors from the same study were profiled to confirm predictive utility of the signature...
May 1, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29707118/identification-of-a-serum-biomarker-panel-for-the-differential-diagnosis-of-cholangiocarcinoma-and-primary-sclerosing-cholangitis
#19
Joy Cuenco, Natascha Wehnert, Oleg Blyuss, Anna Kazarian, Harry J Whitwell, Usha Menon, Anne Dawnay, Michael P Manns, Stephen P Pereira, John F Timms
The non-invasive differentiation of malignant and benign biliary disease is a clinical challenge. Carbohydrate antigen 19-9 (CA19-9), leucine-rich α2-glycoprotein (LRG1), interleukin 6 (IL6), pyruvate kinase M2 (PKM2), cytokeratin 19 fragment (CYFRA21.1) and mucin 5AC (MUC5AC) have reported utility for differentiating cholangiocarcinoma (CCA) from benign biliary disease. Herein, serum levels of these markers were tested in 66 cases of CCA and 62 cases of primary sclerosing cholangitis (PSC) and compared with markers of liver function and inflammation...
April 3, 2018: Oncotarget
https://www.readbyqxmd.com/read/29705791/biliary-tract-cancer-implicated-immune-mediated-pathways-and-their-associated-potential-targets
#20
Noor-Ul-Ain Tariq, Arndt Vogel, Mairead G McNamara, Juan W Valle
There is a well-established link between biliary tract cancers (BTC) and chronic inflammatory conditions such as primary sclerosing cholangitis, chronic cholecystitis, chronic cholelithiasis, liver fluke-associated infestations, and chronic viral hepatic infections. These associated risk factors highlight the potential for development of immune-modulatory agents in this poor-prognostic disease group with limited treatment options. Clinical trials have evaluated the role of immune cells, inflammatory biomarkers, vaccines, cytokines, adoptive cell therapy, and immune checkpoint inhibitors in patients with BTC...
2018: Oncology Research and Treatment
keyword
keyword
28816
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"